CVM · Insider Trading
Cel-Sci Corporation
Every open-market purchase and sale reported by CVM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-01 | Patricia B Prichep | Chief Financial Officer | A | +2,082 | +$4.29K |
| 2026-10-01 | Geert R Kersten | Chief Executive Officer | A | +2,621 | +$5.40K |
| 2026-10-01 | Eyal Talor | Chief Scientific Officer | A | +1,165 | +$2.40K |
| 2026-08-26 | Geert R Kersten | Chief Executive Officer | Buy | +100,000 | +$138.00K |
| 2026-08-17 | Robert Eugene Watson | Director | A | +110,000 deriv. | — |
| 2026-08-17 | Patricia B Prichep | Chief Financial Officer | A | +225,000 deriv. | — |
| 2026-08-17 | Geert R Kersten | Chief Executive Officer | A | +300,000 deriv. | — |
| 2026-08-17 | John Cipriano | Senior Vice President | A | +80,000 deriv. | — |
| 2026-08-17 | Eyal Talor | Chief Scientific Officer | A | +250,000 deriv. | — |
| 2026-08-17 | Bruno Jean-Marie Baillavoine | Director | A | +110,000 deriv. | — |
| 2026-07-01 | Eyal Talor | Chief Scientific Officer | A | +2,307 | +$2.40K |
| 2026-07-01 | Patricia B Prichep | Chief Financial Officer | A | +4,125 | +$4.29K |
| 2026-07-01 | Geert R Kersten | Chief Executive Officer | A | +5,192 | +$5.40K |
| 2026-05-18 | Geert R Kersten | Chief Executive Officer | Buy | +300,000 | +$360.00K |
| 2026-05-14 | Geert R Kersten | Chief Executive Officer | Buy | +100,000 | +$119.00K |
| 2026-04-01 | Patricia B Prichep | Chief Financial Officer | A | +1,336 | +$4.29K |
| 2026-04-01 | Geert R Kersten | Chief Executive Officer | A | +1,682 | +$5.40K |
| 2026-04-01 | Eyal Talor | Chief Scientific Officer | A | +747 | +$2.40K |
| 2026-01-26 | Geert R Kersten | Chief Executive Officer | Buy | +38,023 | +$200.00K |
| 2026-01-05 | Eyal Talor | Chief Scientific Officer | A | +456 | +$2.40K |
| 2026-01-05 | Patricia B Prichep | Chief Financial Officer | A | +815 | +$4.29K |
| 2026-01-05 | Geert R Kersten | Chief Executive Officer | A | +998 | +$5.25K |
| 2025-12-05 | Geert R Kersten | Chief Executive Officer | Buy | +8,389 | +$50.00K |
| 2025-10-02 | Eyal Talor | Chief Scientific Officer | A | +260 | +$2.39K |
| 2025-10-02 | Geert R Kersten | Chief Executive Officer | A | +570 | +$5.24K |
| 2025-10-02 | Patricia B Prichep | Chief Financial Officer | A | +466 | +$4.29K |
| 2025-07-29 | Patricia B Prichep | Chief Financial Officer | A | +12,000 deriv. | — |
| 2025-07-29 | Bruno Jean-Marie Baillavoine | Director | A | +4,000 deriv. | — |
| 2025-07-29 | Robert Eugene Watson | Director | A | +4,000 deriv. | — |
| 2025-07-29 | Eyal Talor | Chief Scientific Officer | A | +15,000 deriv. | — |
| 2025-07-29 | Robert Eugene Watson | Director | Buy | +2,919 | +$20.00K |
| 2025-07-29 | John Cipriano | Senior Vice President | A | +7,500 deriv. | — |
| 2025-07-29 | Geert R Kersten | Chief Executive Officer | A | +25,000 deriv. | — |
| 2025-07-28 | Geert R Kersten | Chief Executive Officer | Buy | +29,197 | +$200.00K |
| 2025-07-01 | Patricia B Prichep | Chief Financial Officer | A | +1,873 | +$4.29K |
| 2025-07-01 | Eyal Talor | Chief Scientific Officer | A | +1,048 | +$2.40K |
| 2025-07-01 | Geert R Kersten | Chief Executive Officer | A | +2,292 | +$5.25K |
| 2025-04-01 | Eyal Talor | Chief Scientific Officer | A | +10,416 | +$2.40K |
| 2025-04-01 | Geert R Kersten | Chief Executive Officer | A | +22,786 | +$5.25K |
| 2025-04-01 | Patricia B Prichep | Chief Financial Officer | A | +15,432 | +$3.56K |
| 2025-01-02 | Geert R Kersten | CEO | A | +12,940 | +$5.18K |
| 2025-01-02 | Patricia B Prichep | Chief Financial & Operations | A | +10,727 | +$4.29K |
| 2025-01-02 | Eyal Talor | Chief Scientific Officer | A | +6,001 | +$2.40K |
| 2024-10-01 | Eyal Talor | Chief Scientific Officer | A | +2,264 | +$2.40K |
| 2024-10-01 | Geert R Kersten | Chief Executive Officer | A | +4,882 | +$5.17K |
| 2024-10-01 | Patricia B Prichep | Sr. VP of Operations | A | +4,047 | +$4.29K |
| 2024-07-01 | Patricia B Prichep | Senior Vice President | A | +3,698 | +$4.29K |
| 2024-07-01 | Eyal Talor | Chief Scientific Officer | A | +2,068 | +$2.40K |
| 2024-07-01 | Geert R Kersten | Chief Executive Officer | A | +4,461 | +$5.17K |
| 2024-05-10 | Robert Eugene Watson | Director | Buy | +20,000 | +$27.80K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Geert R Kersten | Chief Executive Officer | 630,310 | $1.00M |
| Patricia B Prichep | Chief Financial Officer | 19,571 | $31.12K |
| Eyal Talor | Chief Scientific Officer | 10,483 | $16.67K |
| Robert Eugene Watson | Director | 3,733 | $5.94K |
| John Cipriano | Senior Vice President | 2,104 | $3.35K |
| Bruno Jean-Marie Baillavoine | Director | 199 | $316 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CVM quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.